title: [Analysis of combination chemotherapy with docetaxel and nedaplatin for esophageal cancer].
abstract: OBJECTIVE
  There is no standard second line regimen for metastatic or recurrent esophageal cancer. We investigated the feasibility of combination chemotherapy with Docetaxel (DOC) and Nedaplatin (CDGP) as a second-line regimen for metastatic or recurrent esophageal cancer.
  
  
  METHODS
  Patients received DOC (60 mg/m2 intravenously) on day 1 and subsequently CDGP(70 mg/m2 intravenously) on day 1 of each 4-week period thereafter. We analyzed the toxicity and efficacy in 9 patients treated with combination chemotherapy with DOC and CDGP.
  
  
  RESULTS
  The observed Grade 3-4 toxicities were neutropenia and anemia. Three patients had stable disease and 6 patients had progressive disease. The median progression free survival and overall survival were 4.3 and 8.1 months, respectively.
  
  
  CONCLUSIONS
  Combination chemotherapy with DOC and CDGP is considered a feasible second line regimen for metastatic or recurrent esophageal cancer.
authors.affiliation: Dept. of Surgery, Osaka General Medical Center, Osaka, Japan.
authors.forename: Junji
authors.initials: J
authors.lastname: Kawada
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Iwase
authors.forename: Koichi
authors.initials: K
authors.lastname: Deguchi
authors.forename: Shigeyoshi
authors.initials: S
authors.lastname: Higashi
authors.forename: Takashi
authors.initials: T
authors.lastname: Deguchi
authors.forename: Chu
authors.initials: C
authors.lastname: Matsuda
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Tamagawa
authors.forename: Kenichi
authors.initials: K
authors.lastname: Omori
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Nishikawa
authors.forename: Masaya
authors.initials: M
authors.lastname: Nomura
authors.forename: Mari
authors.initials: M
authors.lastname: Takagi
authors.forename: Akiko
authors.initials: A
authors.lastname: Fukui
authors.forename: Yasuhiro
authors.initials: Y
authors.lastname: Tanaka
mesh_terms: D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D000077143:Docetaxel; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology / Q000628:therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D043823:Taxoids / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D009944:Organoplatinum Compounds; D043823:Taxoids; D000077143:Docetaxel; C053989:nedaplatin